Distracted

Alactin is used to slow down the process of physiological lactation.

The active ingredient of the drug is ergoline derivative, related to the associated ergot alkaloid, and showing strong and prolonged prolactin-lowering activity (intensity depends on the size of the portion). The blood indices of prolactin after the administration of the drug decrease after 3 hours (on average), and the effect lasts for 14-20 days. Thus, to stop the release of milk, it is enough to use 1-time use of Alaktin.

Indications Alaktina

It is used in the combined treatment of pituitary adenoma with the release of prolactin on its background, as well as hyperprolactinemia.

It may be prescribed to prevent or suppress the processes of physiological lactation, which begins after childbirth (in connection with medical recommendations).

Release form

The release of drugs is performed in tablets, 2 or 8 pieces inside the pack.

Pharmacodynamics

Due to the introduction of the drug in case of hyperprolactinemia, the blood values of prolactin stabilize (to achieve certain indicators of cabergoline). At the same time, the drug does not affect the secretion processes of other pituitary hormones.

[1], [2], [3], [4]

Pharmacokinetics

In oral administration, the drug is fully absorbed inside the gastrointestinal tract. Eating does not affect the absorption of cabergoline. Blood level Cmax is recorded after 3 hours.

With protein synthesized at a moderate level. When biotransformation is formed several metabolic elements, but only carboxy-ergoline has medicinal activity.

The term of excretion is rather long and in people with hyperprolactinemia it is 80-110 hours. Excreted together with feces and urine.

[5], [6], [7]

Dosing and administration

The drug is taken orally with food.

Inhibition of postpartum lactation.

It is required to use 1-well pill of the drug 1-time for the 1st day after delivery. The size of the therapeutic dose is 1 mg of drug substance. To suppress an already existing lactation, it is required to use 0.25 mg of the drug at 12-hour intervals for a period of 2 days (the total portion size is a maximum of 1 mg).

Therapy for hyperprolactinemia.

To use Alaktin should be 1-2 times a week. Therapy begins with the use of lower doses of drugs - 0.25 or 0.5 mg per week. In accordance with the indications, the dosage can be gradually increased by 0.5 mg per week with a 1-month interval, before the development of drug exposure.

The standard therapeutic dose size is 1 mg per week with possible fluctuations in the range of 0.25-2 mg. During the day, you can use a maximum of 3 mg medication. If required, weekly dosage can be divided into several uses. Usually the separation of the weekly portion occurs when using a dosage of more than 1 mg.

[17], [18], [19], [20], [21]

Use Alaktina during pregnancy

Appropriate testing with adequate control of the use of cabergoline in pregnant women was not performed. Tests involving animals have shown that there is no teratogenic effect, but there is information about the appearance of embryotoxicity and impaired fertility, which are associated with pharmacodynamic parameters.

There is evidence of the occurrence of strong congenital developmental abnormalities or miscarriages after the use of cabergoline in pregnant women. Most often from neonatal malformations musculoskeletal diseases and anomalies of cardiopulmonary nature were noted. There is no information about perinatal disorders and the subsequent development of children after intrauterine effects of cabergoline on them.

It is necessary to verify the absence of pregnancy before the start of treatment and to control the possibility of its occurrence for at least 1 month after the completion of therapy. When conception occurs during treatment, the course should be canceled after pregnancy is diagnosed - in order to limit the effect of the substance on the fetus.

After the discontinuation of Alaktin, it is required to use contraceptives for at least another month.

Since cabergoline inhibits the process of lactation, when breastfeeding the drug is not prescribed.

Cabergoline or its metabolic components were excreted with milk during testing in rats. There is no data on excretion with human maternal milk, but it is recommended to refuse breastfeeding if lactation suppression does not occur after cabergoline use.

[8]

Contraindications

Among the contraindications:

• severe intolerance associated with ergot alkaloids;
• problems with the liver;
• preeclampsia or eclampsia;
• increase in blood pressure after childbirth;
• cardiac valvulopathy;
• presence in the history of psychosis, developed after childbirth.

[9], [10], [11], [12], [13]

Side effects Alaktina

Main adverse events:

• dizziness, depression, drowsiness, headaches, fatigue, loss of consciousness, valvulopathy of cardiac nature and paresthesia;
• decrease in blood pressure, nosebleeds, tachycardia, pain in the sternum area;
• constipation, nausea and stomach pain;
• facial hyperemia and convulsions affecting the gastrocnemius muscles.

[14], [15], [16]

Overdose

The use of Alactin in large portions can cause nausea, hallucinations, gastric disorders, lowering blood pressure, psychosis and vomiting.

[22]

Interactions with other drugs

It is forbidden to combine the drug with other drugs, which include other ergot alkaloids.

Alactin cannot be combined with dopamine antagonists (among them, butyrophenone, metoclopramide with thioxanthene and phenothiazine), as well as with macrolides (erythromycin).

[23], [24]

Storage conditions

Alactin should be maintained at a temperature of no more than 25 ° C.

[25]

Shelf life

Alactin can be used within a 3-year term from the date of manufacture of the drug substance.

Application for children

There is no information regarding the efficacy and safety of administering drugs to persons under the age of 16 years.

[26]

Analogs

Analogs of drugs are drugs Dostinex, Norprolak with Bromkriptina-KV, as well as Bromocriptine-Richter.

[27]

Reviews

Alaktin receives very good reviews from most women.